Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Asensus Surgical (ASXC)
NYSE MKT:ASXC
Holding ASXC?
Track your performance easily
ASXC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.17 - $0.40
Previous Close$0.35
Volume4.00M
Average Volume (3M)3.08M
Market Cap
$94.92M
Enterprise Value$107.57M
Total Cash (Recent Filing)$7.78M
Total Debt (Recent Filing)$20.43M
Price to Earnings (P/E)―
Beta1.67
Next Earnings
Nov 12, 2024EPS Estimate
-$0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.31
Shares Outstanding272,842,574
10 Day Avg. Volume4,191,108
30 Day Avg. Volume3,080,401
Standard Deviation0.57
R-Squared0.02
Alpha-0.00324
Financial Highlights & Ratios
Price to Book (P/B)-8.70
Price to Sales (P/S)9.58
Price to Cash Flow (P/CF)-1.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue10.92
Enterprise Value/Gross Profit-23.50
Enterprise Value/Ebitda-1.35
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Asensus Surgical News
PremiumCompany Announcements
Asensus Surgical Embarks on New Chapter Post-Merger
PremiumPre-Earnings
Is ASXC a Buy, Before Earnings?Bulls Say, Bears Say
Bulls Say
Product AdoptionOver 3,550 surgical procedures were performed, representing 14% year-over-year growth.
Product DevelopmentLUNA Surgical System shows promise with successful preclinical evaluations.
Strategic PartnershipsAsensus' partnership with NVIDIA aims to enhance the development of its Intelligent Surgical Unit capabilities.
Bears Say
Analyst SentimentAnalyst downgrades Asensus Surgical to Neutral from Overweight due to liquidity and balance-sheet concerns.
Financial PerformanceAsensus Surgical reported total revenues of $1.09M, missing the consensus estimate of $1.99M.
Guidance RevisionManagement revised its prior guidance regarding Senhance placements to 8-10 units for 2023, a decrease from previous expectations.
---
Ownership Overview
10.88% Insiders
5.29% Mutual Funds
10.42% Other Institutional Investors
73.41% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ASXC FAQ
What was Asensus Surgical’s price range in the past 12 months?
Asensus Surgical lowest stock price was $0.17 and its highest was $0.40 in the past 12 months.
What is Asensus Surgical’s market cap?
Currently, no data Available
When is Asensus Surgical’s upcoming earnings report date?
Asensus Surgical’s upcoming earnings report date is Nov 12, 2024 which is 9 days ago.
How were Asensus Surgical’s earnings last quarter?
Asensus Surgical released its earnings results on Aug 13, 2024. The company reported -$0.07 earnings per share for the quarter, missing the consensus estimate of -$0.06 by -$0.01.
Is Asensus Surgical overvalued?
According to Wall Street analysts Asensus Surgical’s price is currently Overvalued.
Does Asensus Surgical pay dividends?
Asensus Surgical does not currently pay dividends.
What is Asensus Surgical’s EPS estimate?
Asensus Surgical’s EPS estimate is -$0.04.
How many shares outstanding does Asensus Surgical have?
Asensus Surgical has 272,843,000 shares outstanding.
What happened to Asensus Surgical’s price movement after its last earnings report?
Asensus Surgical reported an EPS of -$0.07 in its last earnings report, missing expectations of -$0.06. Following the earnings report the stock price went down -12.5%.
Which hedge fund is a major shareholder of Asensus Surgical?
Currently, no hedge funds are holding shares in ASXC
---
Asensus Surgical Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
ASXC Sentiment 100%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.8%
Last 30 Days ▲ 1.9%
Last 30 Days ▲ 1.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Fundamentals
Return on Equity
-334.02%
Trailing 12-Months
Asset Growth
-50.87%
Trailing 12-Months
Company Description
Asensus Surgical
TransEnterix, Inc. is a medical device company. It focuses on commercialization of Senhance System, that digitizes laparoscopic minimally invasive surgery. It offers the Senhance Surgical Robotic System, which offers robotic surgery for laparoscopic abdominal and pelvic surgery, as well as limited thoracic operations excluding cardiac and vascular surgery, and the SurgiBot System which refers to the a single-port, robotically enhanced laparoscopic surgical platform. The company was founded by William N. Starling in 2006 and is headquartered in Morrisville, NC.
---
ASXC Earnings Call
Q2 2024
0:00 / 0:00
---
ASXC Stock 12 Month Forecast
Average Price Target
―Technical Analysis
---